Tumor Targeted Radiotherapy for Patients With Localized Prostate Cancer
This is a prospective two arm phase 2 trial investigating the technical and clinical
performance of tumor-targeted (rather than prostate targeted) radiotherapy.
Cohort 1 (Control group): This group consists of patients who have had previous radiation.
This group will not receive any active treatment but will have a biopsy at 3 years from the
time they completed their radiation therapy. Patient in this group will also continue to
have their PSA checked per standard practice
Cohort 2 (Experimental group): Patients in this group will receive one of 2 treatment arms
of their choice. In addition to the MRI-guided prostate biopsy at 3 years and regular
standard of care PSA checks, this group will also complete a quality of life questionnaire
and have regular imaging per standard practice.
Both groups will be followed by the research team per protocol.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Determine rates of Local Control after standard targeted boost radiotherapy in patients with localized prostate cancer.
Cynthia Ménard, MD
University Health Network, The Princess Margaret
Canada: Ethics Review Committee
UHN REB 12-5015-C